Tumor News and Research

RSS

Approval of personalized therapy for lung cancer in Europe will change way of treatment

The recent approval of Europe's first personalized treatment for lung cancer heralds the arrival of a new era for lung cancer treatment that will demand significant changes to the way cancer specialists and other hospital doctors work, a leading expert said today at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

4 May 2010

Researchers explore role of ECoG measurement to improve brain mapping technology

Epilepsy and seizures affect nearly 3 million Americans of all ages, with 200,000 new cases of seizures and epilepsy occurring each year. Epilepsy surgery may be performed in patients who have seizures associated with structural brain abnormalities, such as benign brain tumors and cortical dysplasia, malformations of blood vessels, the genetic disorder tuberous sclerosis, and strokes.

4 May 2010

New study shows people with BAV more likely to have brain aneurysms

A new study shows that people with a common heart defect may also be more likely to have brain aneurysms. The study is published in the May 4, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

4 May 2010

Novel combined immunotherapy promising for treatment of malignant brain tumors

A new Phase I clinical trial conducted at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute in Los Angeles shows that two innovative treatment approaches may safely be combined to treat patients with highly aggressive, malignant brain tumors called gliomas. The results suggest that combining the two therapies might boost their effectiveness and supports the pursuit of additional studies on this approach to treating these tumors.

4 May 2010

BioMarker Strategies receives $1M NCI grant funding to develop SnapPath live tumor cell testing system

BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.

4 May 2010

Researchers evaluate efficacy of GKRS in patients with pituitary adenoma

In 2009, it was estimated that a total of 22,070 new cases of brain and other CNS tumors were diagnosed. Pituitary adenomas represent one of the most common brain tumors. Large studies report that approximately 10-20 percent of the population harbors a pituitary tumor. According to the Central Brain Tumor Registry of the United States, 13.4 percent of all brain and CNS tumors diagnosed in 2009 were located in the pituitary.

4 May 2010

Broccoli component sulforaphane targets and kills breast cancer stem cells

A compound derived from broccoli could help prevent or treat breast cancer by targeting cancer stem cells -- the small number of cells that fuel a tumor's growth -- according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

4 May 2010

NIH awards Hutchinson Center $10.24M for research of breast cancer disparities in Hispanic women

The National Institutes of Health has awarded $10.24 million to Fred Hutchinson Cancer Research Center to lead a five-year study that aims to understand and prevent breast cancer disparities in Hispanic women.

4 May 2010

QIAGEN reports 20% revenue growth in first quarter 2010

QIAGEN N.V. today announced the results of operations for its quarter ended March 31, 2010. Net sales were at the high end of, and adjusted earnings per share for the first quarter 2010 exceeded the guidance provided by the Company on February 9, 2010.

From QIAGEN Manchester Limited 4 May 2010

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced interim study results that showed its doxorubicin prodrug INNO-206 demonstrated statistically significant anti-tumor activity in human myeloma tumor cells growing in immune-deficient mice compared to a control group, while exhibiting significantly less toxicity than doxorubicin even though INNO-206 was administered at much higher doses.

3 May 2010

Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has successfully completed enrollment and treatment of the last patient in its Phase I clinical trial of CUDC-101, Curis' first-in-class HDAC, EGFR and HER2 inhibitor.

3 May 2010

Protein test to determine response of lung cancer patients to erlotinib

Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable, according to new data presented at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

3 May 2010

ExacTrac SV system allows precise targeting of radiotherapy using real-time X-ray images

A system that allows precise targeting of radiotherapy using real-time X-ray images has allowed French doctors to increase the dose of radiation they administered to lung and liver cancers while minimizing harm to nearby healthy tissue, researchers report at the 2nd European Lung Cancer Conference.

3 May 2010

Promising results from combination therapy of pemetrexed concurrent with radiation in lung cancer

The first trial of an important new combination therapy of treatment with the chemotherapy drug pemetrexed concurrent with radiation in lung cancer has delivered promising results, French researchers report at the 2nd European Lung Cancer Conference.

3 May 2010

BSGI improves breast cancer detection

A new study, presented at the American Society of Breast Surgeons Annual Meeting in Las Vegas, found that Breast-Specific Gamma Imaging (BSGI) is highly accurate in monitoring the response of breast cancers to neoadjuvant chemotherapy.

3 May 2010

New research suggests tumor-secreted exosomes inhibit immune response, enhance tumor metastasis

Current research suggests that tumor-secreted exosomes inhibit the immune response, enhancing tumor metastasis. The related report by Liu et al, "Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells," appears in the May 2010 issue of The American Journal of Pathology.

3 May 2010

FDA oks 'vaccine' to treat prostate cancer

Provenge, developed by Dendreon Corporation, is the first approved "treatment that uses a so-called cancer vaccine, a drug that trains the body's own immune system to fight the disease," The New York Times reports.

3 May 2010

Study indicates older women with diabetes have increase risk for colon cancer

A research team led by Mayo Clinic physicians has found that older women with diabetes face a more than doubled risk for some types of colorectal cancer.

3 May 2010

FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer

Tikcro Technologies Ltd. today announced that BioCancell Therapeutics, Inc., concluded the first 18 patient group treated pursuant to a Phase IIb clinical trial of the drug candidate BC-819 for use in superficial bladder cancer. These patients had not responded to conventional treatment.

3 May 2010

Heart and liver transplant recipients at higher risk of developing lung cancer: Researchers

Heart and liver transplant recipients are at particularly high risk of developing lung cancer after receiving the donated organ, researchers report at the 2nd European Lung Cancer Conference. They are advising doctors to screen for such cancers in these patients to maximize the chance of detecting the malignancy early.

3 May 2010

Tumor News and Research

Approval of personalized therapy for lung cancer in Europe will change way of treatment

Researchers explore role of ECoG measurement to improve brain mapping technology

New study shows people with BAV more likely to have brain aneurysms

Novel combined immunotherapy promising for treatment of malignant brain tumors

BioMarker Strategies receives $1M NCI grant funding to develop SnapPath live tumor cell testing system

Researchers evaluate efficacy of GKRS in patients with pituitary adenoma

Broccoli component sulforaphane targets and kills breast cancer stem cells

NIH awards Hutchinson Center $10.24M for research of breast cancer disparities in Hispanic women

QIAGEN reports 20% revenue growth in first quarter 2010

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor

Protein test to determine response of lung cancer patients to erlotinib

ExacTrac SV system allows precise targeting of radiotherapy using real-time X-ray images

Promising results from combination therapy of pemetrexed concurrent with radiation in lung cancer

BSGI improves breast cancer detection

New research suggests tumor-secreted exosomes inhibit immune response, enhance tumor metastasis

FDA oks 'vaccine' to treat prostate cancer

Study indicates older women with diabetes have increase risk for colon cancer

FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer

Heart and liver transplant recipients at higher risk of developing lung cancer: Researchers

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News